Affiris starts Phase II trials of vaccine for Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Vienna-based Affiris is starting Phase II clinical trials of its AD-02 vaccine candidate for Alzheimer's disease targeting beta-amyloid precursor protein after it completed its Phase I testing several months ago. The study should involve up to 420 patients in Austria and five other European countries (Croatia, the Czech Republic, Germany, France and Slovakia).